ANAPTYSBIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.83 USD | -7.64% |
|
-19.81% | -7.42% |
| Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
| Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
Financials (USD)
| Sales 2024 * | 16.39M | Sales 2025 * | 25.59M | Capitalization | 531M |
|---|---|---|---|---|---|
| Net income 2024 * | -178M | Net income 2025 * | -196M | EV / Sales 2024 * | 15.1 x |
| Net cash position 2024 * | 283M | Net cash position 2025 * | 316M | EV / Sales 2025 * | 8.4 x |
| P/E ratio 2024 * |
-3.14
x | P/E ratio 2025 * |
-3.38
x | Employees | 117 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.6% |
More Fundamentals
* Assessed data
More news
Latest transcript on AnaptysBio, Inc.
More recommendations
More press releases
| 1 day | -7.64% | ||
| 1 week | -19.81% | ||
| Current month | -11.94% | ||
| 1 month | -14.42% | ||
| 3 months | -16.29% | ||
| 6 months | +7.19% | ||
| Current year | -7.42% |
1 week
19.79
23.10
1 month
19.7925.62
Current year
19.7927.50
1 year
13.3627.50
3 years
13.3637.89
5 years
10.0079.09
10 years
10.00134.00
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel Faga
CEO | Chief Executive Officer | 44 | 21-11-25 |
Dennis Mulroy
DFI | Director of Finance/CFO | 69 | 20-07-14 |
Paul Lizzul
CTO | Chief Tech/Sci/R&D Officer | 49 | 20-07-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hollings Renton
BRD | Director/Board Member | 77 | 15-06-29 |
Dennis Fenton
BRD | Director/Board Member | 72 | 18-03-04 |
Magda Marquet
BRD | Director/Board Member | 65 | 21-01-17 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.08% | 0 M€ | 0.00% | - | |
| 0.07% | 0 M€ | 0.00% | - | |
| 0.02% | 509 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 19.83 | -7.64% | 363,855 |
| 24-04-17 | 21.47 | +0.61% | 297,067 |
| 24-04-16 | 21.34 | +0.33% | 244,875 |
| 24-04-15 | 21.27 | -6.34% | 267,275 |
| 24-04-12 | 22.71 | -8.17% | 347,661 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
19.83
USD
Average target price
43.5
USD
Spread / Average Target
+119.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.42% | 531M | |
| -3.30% | 102B | |
| +1.79% | 96.07B | |
| -0.44% | 21.66B | |
| -18.35% | 20.77B | |
| -7.45% | 18.53B | |
| -40.31% | 16.91B | |
| -26.84% | 13.79B | |
| +0.59% | 13.33B | |
| +20.86% | 10.94B |
- Stock Market
- Equities
- ANAB Stock
